Not a single offer received for Leverkusen’s Harvetz

Not a single offer received for Leverkusen’s Harvetz – Rolfes

Bayer Leverkusen have not received any offers for Kai Havertz despite persistent speculation linking him with Chelsea, sporting director Simon Rolfes has revealed.

Havertz, 21, has been a revelation in the Bundesliga ever since making his breakthrough as a 17-year-old in the 2016-17 campaign.

The midfielder, who has been played in an increasingly attacking role over the past two years, has scored 29 Bundesliga goals since the start of the 2018-19 campaign, while his haul of 12 this term came alongside six assists.

Widespread speculation suggests it is unlikely he will remain with Leverkusen – who failed to qualify for the Champions League – next term, while Chelsea are said to have positioned themselves as frontrunners for his signature.

Leverkusen are reported to be demanding at least €78million (£70m) for the Germany international, whose national team colleague Timo Werner has already made the switch to Stamford Bridge.

ALSO READ: FA Cup win will justify Arsenal hiring me – Arteta

But Rolfes, a former Leverkusen midfielder who is now in charge of sporting decisions at the club, insists no club has made an offer for Havertz yet.

“So far we have no offer,” Rolfes told Sky Germany. “We know about the interest of clubs, but there is no official offer.

“We have said several times that we will end the season with our entire squad, and that includes Kai. That goes without saying for us.”

Although the Bundesliga season is over, with Leverkusen finishing fifth, Die Werkself are still in the Europa League.

They are due to face Rangers at home next Thursday in the second leg of their last-16 tie, having won 3-1 in Scotland five months ago, prior to the coronavirus pandemic bringing a temporary halt to European football.

Should they get past Rangers, Leverkusen will face either Inter or Getafe in the quarter-finals.

At this point the competition will become a mini-tournament made up of single-legged ties – rather than the usual two-legged contests – after UEFA moved the latter stages to neutral venues in Germany due to the pandemic.

Fotmob

Vanguard

The post Not a single offer received for Leverkusen’s Harvetz – Rolfes appeared first on Vanguard News.

by Temisan Amoye via Vanguard News https://ift.tt/3jYJT3Z Best Known Member of the Cabinet Wikipedia

Comments

Effective Data Governance: IIM-Africa inks partnership deal with Data Management University

President/Chairman of the governing council of IIM-Africa, Dr. Oyedokun Oyewole has said that effective data governance strategy has become more essential for the survival and sustenance of government and businesses, especially with the sudden outbreak of COVID-19 Pandemic. Oyewole said there is the need to ensure that the right policies, processes, technology, and people are in place to effectively manage data while complying with legal and regulatory requirements. He said that as part of the IIM Africa’s commitments towards ensuring global best practices, it has entered into a long-term partnership with DataManagementU.com to bring the finest data management training to industries across Africa. READ ALSO: COVID-19: Foreign affairs minister says first set of Nigerians abroad to be evacuated soon According to the IIM President, the alliance is expected to provide members of the Institute and other professionals across Africa, high standards, internationally-recognized learn...

Remdesivir: The COVID-19 drug helping patients recover faster

A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. PHOTO: AP Remdesivir has been shown to speed up recovery times for patients with COVID-19 in a major US-led trial, becoming the first drug with proven benefit against the disease. Here is what you need to know. – What is remdesivir? – Remdesivir is an experimental, broad spectrum antiviral made by US pharmaceutical Gilead Sciences that was first developed to treat Ebola, a viral hemorrhagic fever. It showed early promise in a primate study in 2016 and was later rolled out for a major trial in the Democratic Republic of Congo, where it was compared against three other medicines. That study concluded in 2019 when it was discontinued because it did not boost survival rates as greatly as two monoclonal antibody drugs, which are lab-engineered immune system proteins. In February, the US National Institute of Allergy and Infectious Diseases (NIAID) announced ...

Naomi Osaka’s statement about withdrawing from French Open

Japan’s Naomi Osaka returns the ball to Romania’s Patricia Maria Tig during their first round match of the French open tennis tournament at the Roland Garros stadium Sunday, May 30, 2021 in Paris. (AP Photo/Christophe Ena) Naomi Osaka tweeted the following statement announcing her withdrawal from the French Open on Monday: “Hey everyone, this isn’t a situation I ever imagined or intended when I posted a few days ago. I think now the best thing for the tournament, the other players and my well-being is that I withdraw so that everyone can get back to focusing on the tennis going on in Paris. ”I never wanted to be a distraction and I accept that my timing was not idea and my message could have been clearer. ”More importantly I would never trivialize mental health or use the term lightly. The truth is that I have suffered long bouts of depression since the US Open in 2018 and I have had a really hard time coping with that. Anyone that knows me knows I’m introverted, and anyone tha...

Thorian

Search This Blog